A Prediction Model of 28-day Mortality in Septic Shock
- Conditions
- Septic Shock
- Registration Number
- NCT04915625
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Brief Summary
This clinical study adopts the design of cohort research, selects the sepsis shock patients admitted to our hospital ICU as the research object, takes the 28-day mortality rate as the outcome index, collects the baseline data of the patient, the severity of the disease, vital signs, the main infection site, the laboratory-related index, the treatment method and other data, screens out the risk factors affecting the sepsis shock 28-day mortality rate and constructs the prediction model accordingly, analyzes the prediction model with the subject's working characteristic curve (ROC). The recognition ability of the model is calculated by the area under the ROC curve (AUC) and the ability of the model to predict 28-day mortality with SOFA and APACHE II.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 530
- Age ≥ 18 years of age, gender-neutral;
- Diagnosed with sepsis shock;
- ICU survives longer than 48 h;
- The preservation of clinical data is complete;
- Diagnosed with sepsis shock within 6 hours of emergency treatment; Combined with people with autoimmune diseases; 3. Organ transplantation or immunosuppressive treatment; 4. Severe heart, liver and kidney insufficiency; 5. Late stage of malignant tumor; 6. Maternity; 7. Referral or referral to another hospital;
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All causes of 28 days mortality 28 days The all-cause mortality rate is measured from the time the ICU is admitted to the hospital and 28 days after admission (regardless of ICU, hospitalization or out-of-hospital mortality).
- Secondary Outcome Measures
Name Time Method ICU hospitalization time 2 years hospitalization time
hospitalization mortality 2 years
Trial Locations
- Locations (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
🇨🇳Hanzhou, Zhejiang, China